DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Clearance marks major shift beyond chemotherapy
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
A major push to sharpen the future of cancer treatment is underway
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Highlights Mirvetuximab-based regimen promise
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
